397 related articles for article (PubMed ID: 16551859)
1. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
Shusterman S; Naranjo A; Van Ryn C; Hank JA; Parisi MT; Shulkin BL; Servaes S; London WB; Shimada H; Gan J; Gillies SD; Maris JM; Park JR; Sondel PM
Clin Cancer Res; 2019 Oct; 25(20):6044-6051. PubMed ID: 31358541
[TBL] [Abstract][Full Text] [Related]
3. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.
Federico SM; McCarville MB; Shulkin BL; Sondel PM; Hank JA; Hutson P; Meagher M; Shafer A; Ng CY; Leung W; Janssen WE; Wu J; Mao S; Brennan RC; Santana VM; Pappo AS; Furman WL
Clin Cancer Res; 2017 Nov; 23(21):6441-6449. PubMed ID: 28939747
[No Abstract] [Full Text] [Related]
4. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
Shusterman S; London WB; Gillies SD; Hank JA; Voss SD; Seeger RC; Reynolds CP; Kimball J; Albertini MR; Wagner B; Gan J; Eickhoff J; DeSantes KB; Cohn SL; Hecht T; Gadbaw B; Reisfeld RA; Maris JM; Sondel PM
J Clin Oncol; 2010 Nov; 28(33):4969-75. PubMed ID: 20921469
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
King DM; Albertini MR; Schalch H; Hank JA; Gan J; Surfus J; Mahvi D; Schiller JH; Warner T; Kim K; Eickhoff J; Kendra K; Reisfeld R; Gillies SD; Sondel P
J Clin Oncol; 2004 Nov; 22(22):4463-73. PubMed ID: 15483010
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
Ribas A; Kirkwood JM; Atkins MB; Whiteside TL; Gooding W; Kovar A; Gillies SD; Kashala O; Morse MA
J Transl Med; 2009 Jul; 7():68. PubMed ID: 19640287
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.
Hank JA; Gan J; Ryu H; Ostendorf A; Stauder MC; Sternberg A; Albertini M; Lo KM; Gillies SD; Eickhoff J; Sondel PM
Clin Cancer Res; 2009 Sep; 15(18):5923-30. PubMed ID: 19737959
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.
Navid F; Sondel PM; Barfield R; Shulkin BL; Kaufman RA; Allay JA; Gan J; Hutson P; Seo S; Kim K; Goldberg J; Hank JA; Billups CA; Wu J; Furman WL; McGregor LM; Otto M; Gillies SD; Handgretinger R; Santana VM
J Clin Oncol; 2014 May; 32(14):1445-52. PubMed ID: 24711551
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
Albertini MR; Hank JA; Gadbaw B; Kostlevy J; Haldeman J; Schalch H; Gan J; Kim K; Eickhoff J; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2012 Dec; 61(12):2261-71. PubMed ID: 22678096
[TBL] [Abstract][Full Text] [Related]
10. A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors.
Bishop MW; Hutson PR; Hank JA; Sondel PM; Furman WL; Meagher MM; Navid F; Santana VM
MAbs; 2020; 12(1):1773751. PubMed ID: 32643524
[TBL] [Abstract][Full Text] [Related]
11. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.
Ladenstein R; Weixler S; Baykan B; Bleeke M; Kunert R; Katinger D; Pribill I; Glander P; Bauer S; Pistoia V; Michon J; Garaventa A; Lode HN
MAbs; 2013; 5(5):801-9. PubMed ID: 23924804
[TBL] [Abstract][Full Text] [Related]
12. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
[TBL] [Abstract][Full Text] [Related]
13. The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
Yamane BH; Hank JA; Albertini MR; Sondel PM
Expert Opin Investig Drugs; 2009 Jul; 18(7):991-1000. PubMed ID: 19548853
[TBL] [Abstract][Full Text] [Related]
14. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; AramendÃa JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
15. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
Frost JD; Hank JA; Reaman GH; Frierdich S; Seeger RC; Gan J; Anderson PM; Ettinger LJ; Cairo MS; Blazar BR; Krailo MD; Matthay KK; Reisfeld RA; Sondel PM
Cancer; 1997 Jul; 80(2):317-33. PubMed ID: 9217046
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.
Murray JL; Cunningham JE; Brewer H; Mujoo K; Zukiwski AA; Podoloff DA; Kasi LP; Bhadkamkar V; Fritsche HA; Benjamin RS
J Clin Oncol; 1994 Jan; 12(1):184-93. PubMed ID: 8270976
[TBL] [Abstract][Full Text] [Related]
17. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
Albertini MR; Yang RK; Ranheim EA; Hank JA; Zuleger CL; Weber S; Neuman H; Hartig G; Weigel T; Mahvi D; Henry MB; Quale R; McFarland T; Gan J; Carmichael L; Kim K; Loibner H; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2018 Oct; 67(10):1647-1658. PubMed ID: 30073390
[TBL] [Abstract][Full Text] [Related]
18. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
[TBL] [Abstract][Full Text] [Related]
19. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.
Furman WL; McCarville B; Shulkin BL; Davidoff A; Krasin M; Hsu CW; Pan H; Wu J; Brennan R; Bishop MW; Helmig S; Stewart E; Navid F; Triplett B; Santana V; Santiago T; Hank JA; Gillies SD; Yu A; Sondel PM; Leung WH; Pappo A; Federico SM
J Clin Oncol; 2022 Feb; 40(4):335-344. PubMed ID: 34871104
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]